Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Collaborative revenue		$ 489
Clinical compound revenue	$ 7
Total revenue	7	489
Operating expenses:
Research and development	8,546	3,385
General and administrative	2,447	1,822
Total operating expenses	10,993	5,207
Operating loss	(10,986)	(4,718)
Other income (expense), net	149	14
Loss before benefit from income taxes	(10,837)	(4,704)
Benefit from income taxes	145	15
Net loss	$ (10,692)	$ (4,689)
Net loss per share:
Basic and Diluted	$ (0.39)	$ (0.21)
Weighted average shares:
Basic and Diluted	27,259,589	22,808,479
Other comprehensive income (loss), net of tax of $0:
Unrealized gains on available-for-sale marketable securities	$ 39
Total comprehensive loss	$ (10,653)	$ (4,689)